Introduction
Gastric cancer is one of the leading causes of cancer death in Japan. Despite curative resection of the primary tumor with extensive dissection of lymph nodes, over half of all patients with advanced gastric cancer die University, between 1985 and 1994. We selected tissue samples from patients who had an invasion beyond the muscularis propria without distant metastases. No histological lymph node metastasis at the time of surgery was confirmed by conventional routine H&E staining. The clinicopathological profiles of the patients are shown in Table 1 . Pathological diagnoses and classification of the gastric cancer were made according to the rules of the Japanese classification of gastric carcinoma [12] . All patients had undergone total or distal gastrectomy with D2 (dissection of all group 1 and group 2 nodes) or more extensive lymph node dissection. No patient had had chemotherapy before the operation, but most of the patients were treated with adjuvant chemotherapy after the operation. Clinical information was available for all patients, and the mean follow-up period was 53.8 months (range, 1-120 months).
All specimens were fixed in formalin and embedded in paraffin, sliced at 5-µm thickness, and attached to glass slides. One section from each lymph node was stained with H&E. We diagnosed no lymph node metastasis in the H&E sections. One additional serial section from each lymph node was stained immunohistochemically, using AE1/AE3 (20 : 1 mixture of AE1 to AE3; IgG1, Boehringer Mannheim, Mannheim, Germany), a pool of monoclonal antibodies reactive to a broad spectrum of human keratins [13] . Tissue sections were rehydrated. The endogenous peroxidase activity We examined 1390 lymph nodes (mean, 27.3 nodes per patient) from the 51 gastrectomy patients. Microinvolvement was defined as the presence of cytokeratin-positive cells in the regional lymph nodes of the stomach. We classified the grade of microinvolvement into three groups: grade 0 (G0), no positive cells in the lymph node; grade 1 (G1), fewer than four discrete positive cells; and grade 2 (G2), more than five positive cells or cell clusters. H&E staining alone did not identify these positive tumor cells. The 2 test was performed to evaluate the relationship between microinvolvement and clinicopathological factors. Survival data were calculated with the KaplanMeier method model and the log rank test was used to assess significant differences between the groups. The level of significance was P Ͻ 0.05.
Results
A single cytokeratin-positive cell in a negative node defined by H&E staining (G1) is shown in Fig. 1 (low magnification) and Fig. 2 (high magnification). Cytokeratin-positive cells showed diffuse staining in the cytoplasm, with intense staining in the cytoplasmic membrane. Figure 3 shows G2 microinvolvement in which more than five cytokeratin-positive cells were observed. Figure 4 also shows G2 microinvolvement, in which cytokeratin-positive cells appeared as small clusters. Of the 1390 lymph nodes that were not confirmed as metastases by H&E staining examination, 67 (4.9%) had cytokeratin-positive cells, which consisted of G1 microinvolvement in 38 lymph nodes (2.7%) and G2 in 29 (2.1%). The incidence of positive nodes per patient varied considerably, from 1 to 12. Of the 67 lymph nodes with microinvolvement, 51 were group 1; 14, group 2; and 2, group 3. Skip microinvolvement to distant nodes (group 2 or group 3) was found in a few negative perigastric nodes (group 1). Of the 51 patients with gastric cancer without histologically positive lymph nodes, immunohistochemical microinvolvement was identified in 22 (43.2%). In regard to the relationship between microinvolvement and various tumor characteristics, microinvolvement increased in accordance with the maximum size of the tumor. In all 4 patients with tumors of more than 80 mm, microinvolvement was identified. The incidence of microinvolvement also increased in accordance with the depth of tumor invasion. Thirteen of 39 patients (33.3%) with depth of invasion within the subserosa (t2) showed microinvolvement. In contrast, 9 of 12 patients (75%) with invasion penetrating the serosa or further into the organ (t3, t4) had microinvolvement. There was no correlation between microinvolvement and patient's sex or age, or the location or histological type of the tumor.
The clinical outcome of patients with and without microinvolvement was not significantly different (Fig.  5) . Three patients died of peritoneal dissemination during the follow-up period. These 3 patients were immunohistochemically diagnosed as having been lymph-node positive. Two of the 3 patients with recurrence were diagnosed with grade 1 microinvolvement, and one of the 3 patients was diagnosed with grade 2. The maximum tumor size in 1 patient was more than 90 mm, and that in the other 2 patients was 40-80 mm. Depth of invasion was t2 in 2 patients and t3 in 1. There were no significant differences between patients with recurrence and those with no recurrence. Of the 29 patients who had no microinvolvement, 2 died of other causes. No patients died of cancer metastasis within the observation period. Figure 6 shows the Kaplan-Meier survival curves for patients with and without microinvolvement in regional lymph nodes who died of recurrence. The difference in survival between those with and without microinvolvement was not significant (P ϭ 0.15).
Discussion
The monoclonal antibody mixture AE1-AE3 is a pool of monoclonal antibodies reactive to a broad spectrum of human keratins in epithelial cells [13] . We performed an immunohistochemical study of 1390 lymph nodes dissected from human gastric cancer that were without lymph node metastasis detectable by conventional histological examination. We used antibodies against cytokeratin to detect microinvolvement. Micrometastases within lymph nodes from breast carcinoma [8, 14, 15] and colorectal carcinoma [6, 7, [16] [17] [18] have been detected immunohistochemically by using anti- bodies to early membrane antigen (EMA), cytokeratin, carcinoembryonic antigen (CEA), and/or S-100 protein.
Cytokeratin is a specific marker among antibodies referred as specific epithelial cell markers [9, 10, 11] . Small numbers of cancer cells in lymph nodes have sometimes been missed by routine histological methods, but immunostaining with cytokeratin antibody has made it possible to detect even a single tumor cell among thousands of normal cells [19] .
We found microinvolvement in 4.8% of the resected lymph nodes and in 43.2% of the patients with nodenegative gastric cancer whose tissues we examined. Siewert et al. [11] reported microinvolvement in 56 of 62 patients with pN0 gastric cancer (90%), by an immunohistological method using cytokeratin antibody. Maehara et al. [10] reported microinvolvement in 15 of 420 (3.6%) nodes and in 8 of 34 patients (23.5%) with cytokeratin-positive cells in the lymph nodes of nodenegative early gastric cancer. Ishida et al. [9] has reported that 197 of 2446 lymph nodes (8.1%) had micrometastases identified by immunostaining for cytokeratin; however, these included samples from node-positive patients. Thus, a substantial proportion of negative H&E-stained nodes is considered to have micrometastases.
It has been reported that meticulous analysis with serial sectioning of whole lymph nodes in which only H&E staining was done resulted in the detection of micrometasis in about 20% of node-negative patients examined by a routine method [20] . The detection rate of metastases within lymph nodes increases if the number of sections increases. However, it is of no use in routine practice to cut multiple serial sections from all lymph nodes. Adell et al. [21] reported that 95% of patients with micrometastases were identified by studying three sections from each of three lymph nodes of colorectal cancer. Therefore, studying only one section may be insufficient for detecting micrometastases. Recently, reverse transcriptase-polymerase chain reaction (RT-PCR) methods have been reported as more sensitive and have been extensively utilized to detect micrometastases in gastric cancer [22] , breast cancer [23] , and colorectal cancer [24] .
As lymph node metastasis is likely to occur together with tumor progression, microinvolvement in gastric cancer increases in accordance with the size of tumor, depth of invasion, and venous invasion. Ishida et al. [9] reported that micrometastases were observed more frequently in diffuse-type gastric cancer, but these results were not found in our study.
Maehara et al. [10] reported that the survival of a cytokeratin-positive group of patients with early gastric cancer was significantly shorter than that of a cytokeratin-negative group. The presence of micrometastases in lymph nodes has been shown to be an indispensable factor in determining the prognosis of gastric cancer patients [9] . In this study, we found no difference in the survival of gastric cancer patients with and without microinvolvement. This is partly because the number of tumors and the follow-up period were limited. However, it must be noted that no patients without microinvolvement died of recurrence. Thus, determination of microinvolvement within lymph nodes is considered to be a more reliable prognostic factor than diagnosing lymph node involvement by conventional methods.
Regional lymph nodes are routinely dissected during gastric cancer surgery. However, it is not clear why many lymph nodes have to be dissected. Baba et al. [25] reported a higher recurrence rate in patients treated with D1 lymph node dissection than in those who received D2/3 dissection, even in patients with nodenegative early gastric cancer. This report suggests the possible presence of micrometastases in lymph nodes of node-negative gastric cancer.
It is uncertain whether cytokeratin-positive cells in lymph nodes will manifest as clinical involvement. During the formation of metastases in lymph nodes, cancer cells are thought to migrate in the lymph vessels, reach the lymph nodes, lodge in the sinus, and proliferate. Chronologically, G1 microinvolvement may mean that the cancer cells have just reached the lymph node, while G2 microinvolvement indicates the initiation of proliferation. However, it is not known how long after their initial arrival in the lymph nodes the cancer cells begin to proliferate, and it is also not known whether tumor cells in lymph nodes are really able to migrate and successfully colonize other organs.
Patients with bone marrow cytokeratin-positive cells showed a significantly shorter disease-free survival than those without cytokeratin-positive cells, but not all patients who had bone marrow tumor cells died [5] . Pantel et al. [26] reported that cytokeratin-positive cells existed in bone marrow, but it is still unclear whether these cells can proliferate or whether they are removed by the host immune response. The possibility of tumor cells proliferating and showing metastasis depends on various factors, such as cell viability, cell characteristics, the host immune response, and the microenvironment. It is not clear whether the cytokeratin-positive cells could grow to macroscopic metastases, but microinvolvement of at least G2 is regarded as metastasis. Further investigations with a greater number of patients and a longer follow-up period will clarify these problems.
